Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

被引：7

作者：

De Filippo, Maria ^{[1
,2
]}

Votto, Martina ^{[1
,2
]}

Caminiti, Lucia ^{[3
]}

Carella, Francesco ^{[4
]}

De Castro, Giovanna ^{[5
]}

Landi, Massimo ^{[6
,7
,8
]}

Olcese, Roberta ^{[9
]}

Panasiti, Ilenia ^{[3
]}

Vernich, Mario ^{[10
]}

Barberi, Salvatore ^{[10
]}

Ciprandi, Giorgio ^{[11
]}

Marseglia, Gian Luigi ^{[1
,2
]}

机构：

[1] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy

[2] Fdn IRCCS Policlin San Matteo, Pediat Clin, Pavia, Italy

[3] Univ Messina, Allergy Unit, Dept Pediat, Messina, Italy

[4] Azienza Osped Univ Policlin Giovanni XXIII, Pediatr Unit, Bari, Italy

[5] Sapienza Univ Rome, Dept Pediat, Rome, Italy

[6] Pediat Natl Hlthcare Syst, Turin, Italy

[7] Italian Natl Res Council, Ist Biomed Immunol Mol, Palermo, Italy

[8] CNR, Inst Biomed Res & Innovat, Dept Biomed, Palermo, Italy

[9] Ist Giannina Gaslini, Allergy Ctr, Dept Pediat, Genoa, Italy

[10] ASST Rhodense, Pediat Unit, Milan, Italy

[11] Casa Cura Villa Montallegro, Allergy Clin, Genoa, Italy

来源：

ALLERGOLOGIA ET IMMUNOPATHOLOGIA | 2022年 / 50卷 / 06期

关键词：

Allergen Immunotherapy; Omalizumab; IgE; Tolerance; Allergic Rhinitis; Asthma; SUBCUTANEOUS IMMUNOTHERAPY; BIOLOGICAL THERAPIES; CHILDREN; PRETREATMENT; COMBINATION; SAFETY; ADOLESCENTS; EFFICACY; UPDATE; ASTHMA;

D O I：

10.15586/aei.v50i6.495

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT. (c) 2022 Codon Publications. Published by Codon Publications.

引用

页码：47 / 52

页数：6